Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- DIA Workshop Focuses on Collaborative Clinical Trials in Asia
October 22, 2007
- R&D NEWS IN BRIEF
October 22, 2007
- SymBio Begins PI Study of SyB-0702 in US
October 22, 2007
- MediciNova Reports Positive PIIa Results for MN-221 for Status Asthmaticus
October 22, 2007
- PMDA Introduces New Training Program to Upgrade Its Reviewers
October 22, 2007
- FDA Accelerates Review of Generics to Promote Their Use
October 22, 2007
- Korosho to Require Overnight Delivery of Generics
October 22, 2007
- Teijin Aims at Share of Over 25% on Market for Osteoporosis Drugs
October 22, 2007
- Need to Promote Use of Generics Stressed at JPA Congress
October 22, 2007
- Eli Lilly Japan to Price Cialis \100 per Tablet Above Competitors"Prices
October 22, 2007
- Lupin of India Acquires Kyowa Pharm. Industry
October 22, 2007
- Alcon to Invest US$3 Bil. in R&D over the Next 5 Years
October 22, 2007
- BUSINESS NEWS IN BRIEF
October 22, 2007
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
October 22, 2007
- Diovan Keeps Top Position for 5 Consecutive Months
October 22, 2007
- MEDICAL DEVICE NEWS IN BRIEF
October 22, 2007
- Major Domestic Companies Must Overcome 2010 Crisis
October 22, 2007
- Medtronic's Implantable Holter ECG Recommended for Fast-Track Review
October 22, 2007
- CFS and Ain Pharmaciez to Merge in April 2008
October 22, 2007
- NEW PRODUCTS
October 15, 2007
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…